emalex

16 items

April 24, 2023

Harmony Biosciences Announces Jeffrey M. Dayno, M.D. Appointed President & Chief Executive Officer
– Dr. Dayno joins Harmony Biosciences Board [...]
March 1, 2023

Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome
– Enrolled patients will receive medication for [...]
January 11, 2023

Emalex Biosciences Publishes Phase 2b Results for Tourette Syndrome Candidate in Pediatrics
– Study data shows investigational new drug, [...]
December 15, 2020

First Patient Dosed in Emalex Biosciences Phase 2 Clinical Trial for Stuttering
Chicago – December 15, 2020 – Emalex Biosciences, [...]
September 1, 2020

Emalex Biosciences Phase 2b Tourette Syndrome Clinical Trial Reaches Enrollment Milestone
– Half of participants are now enrolled [...]
June 3, 2020

Horizon Technology Finance and Emalex Biosciences Announce $15 Million Venture Loan Facility
– Biopharmaceutical company advancing clinical research evaluating novel [...]
October 1, 2018

Jeff Aronin Named One of the 20 Most Influential Leaders in Healthcare for 2018
Paragon CEO Jeff Aronin Recognized by Insights Care [...]
August 14, 2018

Emalex Biosciences Acquires Psyadon Pharmaceuticals to Develop Novel Treatment for Pediatric Tourette Syndrome
CHICAGO – August 14, 2018 – Biopharmaceutical company [...]